- Home
- EPOW vs BOLD Comparison
EPOW vs BOLD Comparison
Compare EPOW & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPOW
- BOLD
- Stock Information
- Founded
- EPOW 2014
- BOLD 2018
- Country
- EPOW China
- BOLD United States
- Employees
- EPOW N/A
- BOLD N/A
- Industry
- EPOW Business Services
- BOLD
- Sector
- EPOW Consumer Discretionary
- BOLD
- Exchange
- EPOW Nasdaq
- BOLD Nasdaq
- Market Cap
- EPOW 24.5M
- BOLD 24.4M
- IPO Year
- EPOW 2021
- BOLD 2024
- Fundamental
- Price
- EPOW $0.92
- BOLD $1.18
- Analyst Decision
- EPOW
- BOLD Buy
- Analyst Count
- EPOW 0
- BOLD 3
- Target Price
- EPOW N/A
- BOLD $4.00
- AVG Volume (30 Days)
- EPOW 17.9K
- BOLD 276.3K
- Earning Date
- EPOW 07-29-2025
- BOLD 08-11-2025
- Dividend Yield
- EPOW N/A
- BOLD N/A
- EPS Growth
- EPOW N/A
- BOLD N/A
- EPS
- EPOW N/A
- BOLD N/A
- Revenue
- EPOW $64,997,741.00
- BOLD N/A
- Revenue This Year
- EPOW N/A
- BOLD N/A
- Revenue Next Year
- EPOW N/A
- BOLD N/A
- P/E Ratio
- EPOW N/A
- BOLD N/A
- Revenue Growth
- EPOW 44.28
- BOLD N/A
- 52 Week Low
- EPOW $0.55
- BOLD $1.00
- 52 Week High
- EPOW $1.36
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- EPOW 45.87
- BOLD N/A
- Support Level
- EPOW $0.88
- BOLD N/A
- Resistance Level
- EPOW $0.96
- BOLD N/A
- Average True Range (ATR)
- EPOW 0.06
- BOLD 0.00
- MACD
- EPOW -0.00
- BOLD 0.00
- Stochastic Oscillator
- EPOW 18.63
- BOLD 0.00
About EPOW Sunrise New Energy Co. Ltd
Sunrise New Energy Co Ltd is engaged in the manufacturing and sale of graphite anode material for EVs and other lithium-ion batteries. The Company's joint venture is in the construction of a manufacturing plant in Guizhou Province. The plant runs on inexpensive electricity from renewable sources that enables the group to be a low-cost and low environmental impact producer of graphite anode material, Its products include GS-1, GS-2, GS-3, GZD-1, GLD-1, and GZ-1.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.